CRBU
Caribou Biosciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.50
P/S
16.80
EV/EBITDA
-1.55
DCF Value
$-2.62
FCF Yield
-59.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
88.2%
Operating Margin
-1329.4%
Net Margin
-1327.4%
ROE
-91.5%
ROA
-82.5%
ROIC
-95.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $3.9M | $-26.5M | $-0.28 |
| FY 2025 | $11.2M | $-148.1M | $-1.59 |
| Q3 2025 | $2.2M | $-27.5M | $-0.30 |
| Q2 2025 | $2.7M | $-54.1M | $-0.58 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.46
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.